AlloVir to Participate in the SVB Securities Global Biopharma Conference
February 01 2023 - 7:00AM
Business Wire
AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage, allogeneic
T-cell immunotherapy company, today announced that Chief Executive
Officer Diana Brainard, M.D., will participate in a fireside chat
at the SVB Securities Global Biopharma Conference on Tuesday,
February 14, 2023, at 10:00 a.m. ET.
A live webcast and archived replay of the fireside chat will be
available on the Investors & Press section of the AlloVir
website at https://ir.allovir.com.
About AlloVir
AlloVir is a leading late clinical-stage cell therapy company
with a focus on restoring natural immunity against life-threatening
viral diseases in pediatric and adult patients with weakened immune
systems. The company’s innovative and proprietary technology
platforms leverage off-the-shelf, allogeneic, single- and
multi-virus-specific T cells for patients with T cell deficiencies
who are at risk from the life-threatening consequences of viral
diseases. AlloVir’s technology and manufacturing process enable the
potential for the treatment and prevention of a spectrum of
devastating viruses with each single allogeneic cell therapy. The
company is advancing multiple mid- and late-stage clinical trials
across its product portfolio. For more information, visit
www.allovir.com or follow us on Twitter or LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230201005346/en/
Media and Investor: Sonia Choi AlloVir
schoi@allovir.com
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Jun 2024 to Jul 2024
AlloVir (NASDAQ:ALVR)
Historical Stock Chart
From Jul 2023 to Jul 2024